Royalty Pharma (RPRX) EBITDA Margin Growth (5y) (2024 - 2026)
Powered by 
Analysis
Royalty Pharma (RPRX) EBITDA Margin Growth (5y) (2024 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 10 | Incyte | 25.61 Bn | 21.07 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -11,449.00 |
| Mar 31, 2026 | 4,927.00 |
| Dec 31, 2025 | 755.00 |
| Sep 30, 2025 | -2,472.00 |
| Jun 30, 2025 | -4,386.00 |
| Mar 31, 2025 | 2,185.00 |
| Dec 31, 2024 | -23,024.00 |
| Sep 30, 2024 | 1,548.00 |
| Jun 30, 2024 | -2,146.00 |